Lisdexamfetamine
Brand names: Vyvanse · Active ingredient: Lisdexamfetamine Dimesylate
In short: Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults . Limitations of Use: Pediatric patients with ADHD younger than 6 years
What is Lisdexamfetamine used for?
Lisdexamfetamine dimesylate capsules are indicated for the treatment of:
Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older
Moderate to severe binge eating disorder (BED) in adults
.
Limitations of Use:
Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older
.
Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate capsules for the treatment of obesity have not been established
.
âš Boxed warning (FDA's strongest warning)
Lisdexamfetamine dimesylate capsules has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate capsules, can result in overdose and death
, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing lisdexamfetamine dimesylate capsules, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout lisdexamfetamine dimesylate capsules treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction
[see
Warnings and Precautions (5.1)
,
Drug Abuse and Dependence (9.2)
].
Lisdexamfetamine dosage
Prior to treating patients with lisdexamfetamine dimesylate capsules, assess:
for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam)
.
the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating lisdexamfetamine dimesylate capsules
.
Take lisdexamfetamine dimesylate capsules orally in the morning with or without food; avoid afternoon doses because of the potential for insomnia. Lisdexamfetamine dimesylate capsules may be administered in one of the following ways:
Information for lisdexamfetamine dimesylate capsules:
Swallow lisdexamfetamine dimesylate capsules whole, or
Open capsules, empty and mix the entire contents with yogurt, water, or orange juice. If the contents of the capsule include any compacted powder, a spoon may be used to break apart the powder. The contents should be mixed until completely dispersed. Consume the entire mixture immediately. It should not be stored. The active ingredient dissolves completely once dispersed; however, a film containing the inactive ingredients may remain in the glass or container once the mixture is consumed.
Lisdexamfetamine dimesylate capsules can be substituted with lisdexamfetamine dimesylate chewable tablets on a unit per unit/mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet)
.
Do not take anything less than one capsule per day. A single dose should not be divided.
The recommended starting dosage in adults and pediatric patients 6 years and older is 30 mg once daily in the morning. Dosage may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals up to maximum recommended dosage of 70 mg once daily
.
The recommended starting dosage in adults is 30 mg once daily to be titrated in increments of 20 mg at approximately weekly intervals to achieve the recommended target dose of 50 mg to 70 mg once daily. The maximum recommended dosage is 70 mg once daily
. Discontinue lisdexamfetamine dimesylate capsules if binge eating does not improve.
In patients with severe renal impairment (GFR 15 to < 30 mL/min/1.73 m
2), the maximum dosage should not exceed 50 mg once daily. In patients with end stage renal disease (ESRD, GFR < 15 mL/min/1.73 m
2), the maximum recommended dosage is 30 mg once daily
.
Agents that alter urinary pH can impact urinary excretion and alter blood levels of amphetamine. Acidifying agents (e.g., ascorbic acid) decrease blood levels, while alkalinizing agents (e.g., sodium bicarbonate) increase blood levels. Adjust lisdexamfetamine dimesylate capsules dosage accordingly
.
How to take Lisdexamfetamine — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Abuse, Misuse, and Addiction
Educate patients and their families about the risks of abuse, misuse, and addiction of lisdexamfetamine dimesylate capsules, which can lead to overdose and death, and proper disposal of any unused drug
[see
Warnings and Precautions (5.1)
,
Drug Abuse and Dependence (9.2)
,
Overdosage (10)
]. Advise patients to store lisdexamfetamine dimesylate capsules in a safe place, preferably locked, and instruct patients to not give lisdexamfetamine dimesylate capsules to anyone else.
Risks to Patients with Serious Cardiac Disease
Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with lisdexamfetamine dimesylate capsules use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease
.
Increased Blood Pressure and Heart Rate
Instruct patients that lisdexamfetamine dimesylate capsules can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects. …
Warnings & precautions
Do not take this medicine if: Lisdexamfetamine dimesylate capsules are contraindicated in patients with:
Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports
.
Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis
.
Lisdexamfetamine dimesylate capsules has a high potential for abuse and misuse. The use of lisdexamfetamine dimesylate capsules exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Lisdexamfetamine dimesylate capsules can be diverted for non-medical use into illicit channels or distribution
. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate capsules, can result in overdose and death
, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing lisdexamfetamine dimesylate capsules, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store lisdexamfetamine dimesylate capsules in a safe place, preferably locked, and instruct patients to not give lisdexamfetamine dimesylate capsules to anyone else. Throughout lisdexamfetamine dimesylate capsules treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction. …
Lisdexamfetamine side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules
Hypertensive Crisis When Used Concomitantly with Monoamine Oxidase Inhibitors
Abuse, Misuse, and Addiction
[see
Boxed Warning
,
Warnings and Precautions (5.1)
, and
Drug Abuse and Dependence (9.2
,
9.3)]
Risks to Patients with Serious Cardiac Disease
Increased Blood Pressure and Heart Rate
Psychiatric Adverse Reactions
Long-Term Suppression of Growth in Pediatric Patients
Peripheral Vasculopathy, including Raynaud’s phenomenon
Serotonin Syndrome
Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Attention Deficit Hyperactivity Disorder
The safety data in this section is based on data from the 4-week controlled parallel-group clinical studies of lisdexamfetamine dimesylate capsules in pediatric and adult patients with ADHD
. …
Drug interactions
MAO Inhibitors (MAOI)
Clinical Impact | MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results.
Intervention | Do not administer lisdexamfetamine dimesylate capsules during or within 14 days following the administration of MAOI
.
Serotonergic Drugs
Clinical Impact | The concomitant use of lisdexamfetamine dimesylate capsules and serotonergic drugs increases the risk of serotonin syndrome.
Intervention | Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during lisdexamfetamine dimesylate capsules initiation or dosage increase. If serotonin syndrome occurs, discontinue lisdexamfetamine dimesylate capsules and the concomitant serotonergic drug(s)
.
CYP2D6 Inhibitors
Clinical Impact | The concomitant use of lisdexamfetamine dimesylate capsules and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of lisdexamfetamine dimesylate capsules compared to the use of the drug alone and increase the risk of serotonin syndrome. …
About this medicine
Lisdexamfetamine dimesylate, a CNS stimulant, is for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-
N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate. The molecular formula is C
17H
33N
3O
7S
2, which corresponds to a molecular weight of 455.59. The chemical structure is:
Lisdexamfetamine dimesylate is a white to off-white powder that is soluble in water (986 mg/mL).
Lisdexamfetamine dimesylate capsules contain 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg of lisdexamfetamine dimesylate (equivalent to 5.8 mg, 11.6 mg, 17.3 mg, 23.1 mg, 28.9 mg, 34.7 mg, and 40.5 mg of lisdexamfetamine).
Inactive ingredients: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide and sodium lauryl sulfate. The ink ingredients common for all strengths are shellac, propylene glycol, strong ammonia solution, black iron oxide and potassium hydroxide.
Each strength capsule also contains colorant ingredients in the capsule shell as follows:
10 mg: FD&C Red No. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e928c7e6-c889-4854-a9c1-e23fb860ba8e. Read the full official label on DailyMed.
Related medicines
Tirzepatide Methylphenidate Amphetamine Orlistat Serdexmethylphenidate and Dexmethylphenidate Benzphetamine Phendimetrazine Centanafadine